Furthermore, dasatinib in combination with the DC-vaccine upregulated Type-1 T cell-recruiting CXCR3-ligand chemokines in the tumor stroma, which correlated with the activation and recruitment of Type-1, vaccine-induced CXCR3+CD8+ TILs and CD11c+ DC into the tumor. Here, CD8A is linked to neoplasm.